Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet

Yueting Dong¹, Zhiye Xu¹, Ziyi Zhang¹, Xueyao Yin¹, Xihua Lin², Hong Li³ and Fenping Zheng¹

¹Department of Endocrinology, Sir Run Run Shaw Hospital Affiliated with School of Zhejiang University, Hangzhou, Zhejiang, People's Republic of China
²Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Sir Run Run Shaw Hospital Affiliated with School of Zhejiang University, Hangzhou, Zhejiang, People's Republic of China

Abstract

Liver X receptors (LXR) are deemed as potential drug targets for atherosclerosis, whereas a role in adipose tissue expansion and its relation to insulin sensitivity remains unclear. To assess the metabolic effects of LXR activation by the dual LXRα/β agonist T0901317, C57BL/6 mice fed a high-fat diet (HFD) were treated with T0901317 (30 mg/kg once daily by intraperitoneal injection) for 3 weeks. Differentiated 3T3-L1 adipocytes were used for analysing the effect of T0901317 on glucose uptake. The following results were obtained from this study. T0901317 reduced fat mass, accompanied by a massive fatty liver and lower serum adipokine levels in HFD mice. Increased adipocyte apoptosis was found in epididymal fat of T0901317-treated HFD mice. In addition, T0901317 treatment promoted basal lipolysis, but blunted the anti-lipolytic action of insulin. Furthermore, LXR activation antagonised PPARγ target genes in epididymal fat and PPARγ-PPRE-binding activity in 3T3-L1 adipocytes. Although the glucose tolerance was comparable to that in HFD mice, the insulin response during IPGTT was significantly higher and the insulin tolerance was significantly impaired in T0901317-treated HFD mice, indicating decreased insulin sensitivity by T0901317 administration, and which was further supported by impaired insulin signalling found in epididymal fat and decreased insulin-induced glucose uptake in 3T3-L1 adipocytes by T0901317 administration. In conclusion, these findings reveal that LXR activation impairs adipose expansion by increasing adipocyte apoptosis, lipolysis and antagonising PPARγ-mediated transcriptional activity, which contributes to decreased insulin sensitivity in whole body. The potential of LXR activation being a therapeutic target for atherosclerosis might be limited by the possibility of exacerbating insulin resistance.

Key Words

- liver X receptor (LXR)
- peroxisome proliferator-activated receptor gamma (PPARγ)
- adipose expansion
- insulin resistance
Introduction

Adipose tissue is a key regulator of energy balance, playing an active role in lipid storage and buffering and synthesising and secreting a wide range of fatty acids and adipokines into the circulation that influence systemic metabolism (Romacho et al. 2014). There is strong evidence showing that dysfunction of adipose tissue plays a critical role in the development of insulin resistance and diabetes mellitus (Abranches et al. 2015, Jankovic et al. 2015). A classical paradigm is that the more adipose tissue, the higher the prevalence of metabolic diseases, and it is this relationship that has interested researchers (Despres & Lemieux 2006). However, recent studies have suggested that the factor linking obesity and insulin resistance may not be the absolute amount of fat accumulated but the mismatch between energy surplus and storage capacity (Lionetti et al. 2009). Allowing adipose tissue to store more lipids may prevent secondary metabolic complications caused by lipids being deposited in non-adipose organs. Thus, the ability of adipose tissue to expand and match the storage needs of energy surplus may be a key determinant in protection against the metabolic syndrome associated with obesity (Murdolo et al. 2013).

Adipose tissue mass is determined by processes governing adipocyte size and number (Hirsch & Han 1969). The size of adipocytes increases because of increased storage of triglycerides from dietary sources or endogenous lipogenic pathways, whereas adipocyte number increases as a result of increased proliferation and differentiation (Roncari et al. 1981). Decreases in adipose tissue mass may involve the loss of lipids through lipolysis and the loss of mature fat cells through apoptosis (Alkhouri et al. 2010). Peroxisome proliferator-activated receptor (PPARγ) is a critical regulator of adipocyte tissue mass. The activation of PPARγ leads to adipocyte differentiation and fatty acid storage (Cock et al. 2004, Medina-Gomez et al. 2007). Moreover, the expansion of adipose tissue associated with obesity may be based on a hyperplastic response of the adipose tissue regulated by PPARγ rather than just on hypertrophy of the mature adipocytes, thus resulting in adipose tissue with smaller but more numerous adipocytes. These smaller adipocytes retain insulin sensitivity with the secretion of insulin-sensing adipokines. This occurs in a mouse model that is heterozygous for PPARγ, which shows improved insulin sensitivity and protection from lipotoxicity despite increased fat mass (Miles et al. 2000, Yamauchi & Kadowaki 2001).

Liver X receptors (LXR), including two isoforms of α and β, are members of the nuclear receptor family. Most studies of LXR have been performed in non-adipose tissue, showing a positive role of LXR in central metabolic pathway regulation including cholesterol, glucose and lipid homeostasis; however, results in recent years suggest that LXR may have important modulatory roles in adipose tissue (Nomiyama & Brummer 2008, Laurencikiene & Ryden 2012). However, studies have reported inconsistent or even contradictory results with regard to the role of LXR in regulating adipogenesis, lipogenesis and insulin sensitivity (Juvet et al. 2003, Hummasti et al. 2004). Previous reports demonstrated that LXR agonists could exhibit potent anti-diabetic effect by inhibiting hepatic gluconeogenesis, but simultaneously induce excessive triglyceride (TG) accumulation in the liver in animal models (Cao et al. 2003, Chisholm et al. 2003, Laffitte et al. 2003). It is generally believed that LXR-induced hepatic steatosis results from increased de novo lipogenesis (DNL) (Chisholm et al. 2003). However, recent study using analysis of dynamic adaptations in parameter trajectories (ADAPT) revealed that the hepatic influx of free fatty acids instead of DNL was the major contributor to hepatic TG accumulation in the early phase of LXR activation (Hijmans et al. 2015). Adipose tissue is the main source of fatty acids, it is still questionable that whether LXR activation could impair TG storage in adipose tissue and lead to ectopic fat deposition. The link between adipose tissue and liver with regard to LXR has been established by Beaven and coworkers (Beaven et al. 2013). They have shown that loss of LXR impairs hepatic lipogenesis, accompanied by a reciprocal increase in adipose lipid storage, by promoting adipose PPARγ pathway activity, indicating possible cross-talk between LXR and PPARγ in adipose tissue. Cross-talk between LXR and PPARγ in adipose tissue is also supported by our previous study that showed an antagonising effect of LXR on PPARγ in the regulation of adiponectin expression (Zheng et al. 2014).

Activation of PPARγ in adipose tissue by thiazolidinedione ligands promotes adipose lipid storage and secondarily increases insulin sensitivity in liver and muscle (Derosa & Maffioli 2012). However, the role of LXR in the alteration of adipose expansion and its relation to insulin resistance has not been studied. Furthermore, whether the possible interference of the PPARγ pathway in adipose tissue by LXR activation results in the impairment of adipose expansion and thus impairs insulin sensitivity needs to be clarified to comprehensively understand the net outcome of the advantageous and disadvantageous effects of LXR activation.
Methods and materials

Reagents

The dual LXRx/β agonist T0901317 was purchased from Cayman Chemical Company and pioglitazone was purchased from Sigma-Aldrich. In animal experiments, T0901317 was solubilised in a vehicle containing 3% DMSO in PBS and administered by intraperitoneal (i.p.) injection at a dose of 30 mg/kg body weight once daily. In cellular experiments, T0901317 was prepared in a solution of 1:1 DMSO:PBS at a concentration of 1 mM, and pioglitazone was solubilised in DMSO at a concentration of 20 mM for further dilution with cell medium.

Culture and differentiation of 3T3-L1 cells

3T3-L1 cells were purchased from the American Type Culture Collection (ATCC) and were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% foetal bovine serum (FBS, Bio-rad) and 100 IU/mL penicillin/streptomycin at 37°C in an atmosphere of 5% CO₂ and 95% humidity. Two days post-confluent cells (designated as Day 0) were induced to differentiate into adipocytes by the addition of differentiation mixture with DMEM containing 10% FBS, 10 μg/mL insulin, 0.5 mM 3-isobutyl-1-methykanthine (IBMX) and 1 μM dexamethasone. Two days later, culture medium was changed to DMEM supplemented with 10% FBS and 10 μg/mL insulin for 2 days. The culture medium was then replaced every other day with DMEM containing 10% FBS for different periods until day 10.

Glucose uptake analysis

Glucose uptake activity was measured using a fluorescent d-glucose analogue 2-[N-(7-nitrobenz-2-oxa-1,3-diaz-ol-4-yl)amino]-2-deoxy-d-glucose (2-NBDG, Invitrogen) in differentiated 3T3-L1 cells. Briefly, differentiated 3T3-L1 cells in 12-well plates were treated with different concentrations of T0901317 (0, 1.0 and 10.0 μM) for 24 h. Then, cells were washed with Dulbecco’s phosphate buffered saline (DPBS) and incubated with 100 mM insulin in glucose-free DMEM for 10 min, and 60 μM 2-NBDG was added to the medium for another 1 h. The medium was then washed twice with cold DPBS to remove free 2-NBDG. The cells in each well were suspended with DPBS after trypsinisation and subsequently transferred to 96 black well fluorescence plates. The fluorescence intensity of cellular 2-NBDG in each well was measured at an excitation wavelength of 485 nm and an emission wavelength of 535 nm using a fluorescent microplate reader.

Electrophoretic mobility shift assay

Differentiated 3T3-L1 cells were treated with DMSO, 10 μM T0901317 and 3 μM pioglitazone or co-treated with 10 μM T0901317 and 3 μM pioglitazone for 24 h, and nuclear protein was extracted and quantified. Electrophoretic mobility shift assay (EMSA) was performed using double-stranded biotin-labelled oligo probes of PPRE (Beyotime Biotechnology, Haimen, China). PPAR consensus oligo sequences were as follows: 5′-CAA AAC TAG GTC AAA GGT CA-3′ and 3′-GTT TTG ATC CAG TTT CCA GT-5′. PPAR-mutant oligo sequences were as follows: 5′-CAA AAC TAG CAC AAA GCA CA-3′ and 3′-GTT TTG ATC GTG TTT CGT GT-5′. To investigate DNA–protein interaction, 1 μL of oligo probe was incubated with nuclear extract (20 μg), EMSA/gel-shift-binding buffer and nuclease-free water for 20 min at room temperature in a total volume of 10 μL. Unlabelled oligo probe was used for the cold probe competitive reaction, and unlabelled mutant oligo probe was used as the mutation probe for the cold competitive reaction. Anti-rabbit PPAR γ antibody (Cell Signaling Technology) was added for super-shift reaction. The reaction mixture was subjected to electrophoresis (100 V in 0.5× Tris-buffered EDTA solution at room temperature) using 8% non-denaturing polyacrylamide gels containing 3% glycerol, and then transferred to a positively charged nylon membrane (Beyotime Biotechnology, Haimen, China), UV cross-linked and blocked. After incubation with 5 μL streptavidin–HRP conjugate, immunoreactive proteins were detected using a chemiluminescent ECL assay kit (Millipore).

Animals

All animal care procedures and methods were approved by the Animal Care Committee of Zhejiang University. Male C57BL/6 mice (aged 8 weeks) were purchased from Slack Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China). A cohort of 36 mice were housed singly and maintained on a 12-h light–darkness cycle. After 1 week of habituation fed on regular chow diet (normal diet (ND), carbohydrate, 63.92%; protein, 26.18%; fat, 9.9%), animals were weighed and divided into two groups: the high-fat diet (HFD) group (n=24) was fed a HFD (35% carbohydrate, 20% protein and 45% fat) and the ND control group (n=12, ND mice).
After 12 weeks, the HFD group was further randomised into two groups of 12 mice. HFD mice were treated for 3 weeks with 30 mg/kg T0901317 (n = 12, T0901317-treated HFD mice) or the vehicle (3% DMSO in PBS, n = 12, HFD mice) once daily by i.p. injection. This dose has been shown to be effective in the treatment of atherosclerosis (Chen et al. 2009). The ND control group also received the same vehicle treatment by i.p. injection. Body weight was recorded once a week, and food intake was monitored every day.

**In vivo glucose homeostasis assays**

After 3 weeks of treatment, intraperitoneal glucose tolerance tests (IPGTT) and intraperitoneal insulin tolerance tests (ITT) were carried out. Half of the mice (n = 5–6 per group) were injected i.p. with glucose (1.5 g/kg body weight) following an overnight fast, and blood glucose levels were tested from tail blood using One Touch Ultra glucose strips (LifeScan, PA, USA) at 0 (basal), 15, 30, 60 and 120 min. Tail blood was also sampled at each time point for insulin measurements. The remaining mice (n = 5–6 per group) were subjected to ITT. Mice were fasted for 4 h prior to i.p. injection of insulin at a dose of 0.5 IU/kg body weight. Blood samples were collected from the tail at 0, 15, 30, 60 and 120 min, and glucose levels were measured immediately by One Touch Ultra glucose strips (LifeScan).

After these tests followed by two-day recovery (during which period, intraperitoneal injection of T0901317/vehicle was continued), all mice were fasted for 12 h and injected i.p. with saline (n = 5–6 per group) or insulin (10 U/kg body weight, n = 5–6 per group) and killed 10 min later by cervical dislocation. Blood samples were obtained and serum was collected and stored at −80°C immediately. Liver, epididymal, peri-renal and inguinal fat pads were carefully excised and weighed, and the pancreas was also dissected. After rinsing in pre-cooled PBS, part of the tissue was placed in storage tubes in a dry ice bath until the end of experiment, and then stored at −80°C for later protein, RNA extraction and preparation of frozen sections and liver homogenate for triglyceride content measurements, whereas the other part was fixed in 4% formaldehyde for routine pathological staining.

**Blood and liver sample assays**

Serum insulin concentrations were determined using the insulin (mouse) EIA kit (Millipore). Adiponectin levels in the fasted serum were measured with the adiponectin (murine) EIA kit (Millipore). NEFA and leptin levels in the fasted serum were measured with the FFA assay kit (Cayman Chemical) and the mouse leptin ELISA kit (Millipore). Triglyceride levels in the fasting serum and liver were measured with mouse TG quantification colorimetric kit (BioVision). All kits were used according to the manufacturer’s protocols.

**Histological analysis of adipose tissue and liver**

Adipose, liver and pancreatic tissues fixed in 4% formaldehyde were then embedded in OCT compound and cut into sections (thickness, 4 μm) according to a standard protocol. The sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope. Size of adipocytes and areas of islets were analysed using Image Pro-plus 6.0 software on H&E staining sections. Frozen liver sections (thickness, 5 μm) were stained with Oil Red O to assess the hepatic lipid content. The extent of adipocyte apoptosis in epididymal fat was determined using a TUNEL kit (Roche Diagnostics). To quantify apoptosis, 10 visual fields at 400× from each section were analysed for TUNEL-positive cells. A TUNEL index was determined using the following formula: (number of stained cells/total number of cells) × 100. Immunohistochemical staining was carried out to determine insulin (rabbit anti-mouse, 1:200; Santa Cruz) levels in pancreatic tissue sections using standard protocols. An anti-rabbit horseradish peroxidase-linked secondary antibody and diaminobenzidine (Beijing Zhongshan Goldenbridge Company, Beijing, China) were used to detect specific binding for insulin, and sections were counterstained with hematoxylin. Picosirisius staining for epididymal fat sections was carried out for collagen with picrosirisius red solution (picrosirisius 0.4 g in saturated aqueous solution of picric acid 100 mL) and viewed under light microscopy.

**Quantitative real-time RT-PCR**

Total RNA was isolated using TRIzol (Invitrogen) and reverse-transcribed with random hexamers using TaqMan reverse-transcription reagents kit (Applied Biosystems) according to the manufacturer’s protocol. Real-time PCR was performed using the 7500 real-time PCR system (Applied Biosystems) and SYBR Green qPCR Kit (TaKaRa). Relative expression was normalised to that of Gapdh as an internal control for quantification of individual mRNA species and calculated using the formula

\[
\Delta \Delta C_{\text{amplification}} = \Delta C_{\text{sample}} - \Delta C_{\text{control}}
\]

where \( \Delta C_{\text{amplification}} \) is the difference in amplification values between the sample and control, \( \Delta C_{\text{sample}} \) is the difference in amplification values between the sample and the internal control, and \( \Delta C_{\text{control}} \) is the difference in amplification values between the control and the internal control.
2(−ΔΔC_{\text{T}}). Primer sets were listed in Supplementary Table 1 (see section on supplementary data given at the end of this article).

**Western blotting**

Equal amounts of protein (50 µg) denatured by boiling were separated by 10% SDS-polyacrylamide gel electrophoresis, transferred to an Immobilon PVDF membranes (Millipore) and blocked with 5% non-fat milk for 1 h at room temperature. Membranes were then incubated with primary antibodies (diluted 1:1000) including anti-rabbit cleaved caspase 3 and 9, cleaved PARP, phosphorylated HSL (s660, s565 and s563), HSL, ATGL, perilipin (PLIN1), phosphorylated Akt, Akt, GLUT4 (plasma membrane protein) and β-actin (Cell Signaling Technology) at 4°C overnight. After incubation with horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies at room temperature for 1 h, immunoreactive proteins were detected using a chemiluminescent ECL assay kit (Millipore).

**Statistical analysis**

Data are expressed as means±S.E.M. (in vivo studies) or means±S.D. (in vitro studies). Differences between the means of individual groups were analysed with independent t-tests or one-way ANOVA and LSD multiple range tests. Two-way repeated measures were used for comparisons between glucose and insulin levels of IPGTT or ITT using the statistical software package SPSS 16.0. A significant difference was defined as \( P<0.05 \). Each in vitro experiment was conducted in triplicate.

**Results**

**LXR activation reduces fat mass accompanied by hepatomegaly and hypertriglyceridemia in mice fed a HFD**

To determine the consequence of LXR activation in obesity, C57BL/6 mice were fed a high-fat diet for 12 weeks to induce obesity and subsequently treated for 3 weeks with dual LXRα/β agonist T0901317. Figure 1A shows growth curves of C57BL/6 mice fed a high-fat diet or ND over a 15-week period. Mice fed a high-fat diet had higher body weight than those on a ND from 8 weeks (week 8: ND=26.1±0.7 g; HFD=28.5±0.6 g; HFD+T0901317=28.7±0.8 g, \( P<0.05 \)), whereas the body weight of HFD mice in the presence or absence of 3 weeks of T0901317 (30 mg/kg per day) treatment was comparable (week 15: HFD=31.4±0.7 g; HFD+T0901317=31.0±0.8 g, \( P>0.05 \), Fig. 1A). Consistent with the body weight, the food intake between them was also similar (Fig. 1B). Unexpectedly, T0901317 administration significantly decreased white fat mass including epididymal (Fig. 1C and D), peri-renal and inguinal adipose tissues (Fig. 1E) as normalised to body weight, whereas liver weight in T0901317-treated HFD mice was doubled than that of HFD mice with pale appearance (Fig. 1D and E). In the histological analysis, the adipocyte size was significantly reduced in the T0901317-treated HFD mice compared to that in HFD mice (Fig. 1F and G). However, substantial lipid accumulation in the livers of T0901317-treated HFD mice was confirmed by histological staining with H&E (Fig. 1H) and red oil (Fig. 1I), as well as the elevated triglyceride levels in the liver (Fig. 1J). The serum TG level was significantly higher (Fig. 1K), whereas adipokines of adiponectin and leptin secretion into the circulation were significantly lower in T0901317-treated HFD mice than those in HFD mice (Fig. 1L and M).

**LXR activation promotes adipocyte apoptosis and inflammation in epididymal fat**

To clarify whether the morphological changes in adipose tissue of T0901317-treated mice were associated with decreased cell numbers, apoptotic cells in the adipose tissue of epididymal fat were assessed. There was no difference in apoptotic nuclei numbers in epididymal fat between mice on ND and HFD with vehicle treatment; however, increased apoptosis was indicated by a 3.5-fold increase in TUNEL immunoreactivity in nuclei in epididymal fat of T0901317-treated HFD mice as compared with that in HFD mice (Fig. 2A and B). Consistently, protein levels of cleaved caspase 9, caspase 3 and PARP, typical molecules of the apoptotic pathway, were all increased by T0901317 treatment (Fig. 2C and D). Moreover, HFD elevated the expression levels of inflammatory factors including F4/80 and Mcp1 in epididymal fat, which were further exacerbated by T0901317 treatment. Additionally, administration of T0901317 increased the expressions of Tnfα and Il6 in HFD mice (Fig. 2E). Furthermore, compared with ND mice, more total collagen deposition was found in epididymal fat of HFD mice detected by picrosirius staining viewed under visible light, consistently with increased Col6a1 and Mmp2 and Mmp9 expressions. However, there was no difference in total collagen deposition or collagen gene expression levels (except Mmp2) between HFD mice with or without treatment T0901317 (Fig. 2F and G).
LXR activation increases lipolysis and inhibits PPARγ-mediated transcriptional activity

To demonstrate the mechanism involving the relationship between T0901317 treatment and decreased fat mass along with hyperlipidaemia, we further investigated the basal lipolysis process, as well as the insulin-induced antilipolytic action. As shown in Fig. 3A, HFD mice experienced higher fasting FFA levels in circulation than ND mice, which were further elevated by T0901317 administration.
T0901317-treated HFD mice (Fig. 3B and C). Insulin is known to suppress lipolysis by inactivating HSL; we thus investigated the phosphorylated forms of HSL levels in epididymal fat in HFD mice administrated with insulin. Indeed, HSL phosphorylation (s660) levels (but not s563 and s565) and its upstream protein of ATGL were significantly higher in epididymal fat of T0901317-treated HFD mice (Fig. 3D and E).

We next measured the mRNA levels of several genes involved in lipogenesis in epididymal fat. As expected, HFD mice had higher expression levels of Srebp-1c and Fasn, instead of Ppary, Acc and Pgc-1a in epididymal fat than ND mice. Surprisingly, T0901317 treatment further induced the expressions of Srebp-1c, Fasn and Ppary without affecting Acc and Pgc-1a despite the fat mass reduction in HFD mice (Fig. 3F).

PPARγ is known to be a powerful promoter of lipogenesis and adipogenesis in adipose tissue, and it plays a critical role in adipose expansion. Regarding to the contrary pattern of PPARγ and fat mass reduction, we
LXR impairs adipose expansion and function

Y Dong and others

LXR activation induces lipid accumulation in the liver

Generally, increased lipolysis and FFA secretion from adipose tissue lead to ectopic fat accumulation, which was indeed found in T0901317-treated HFD mice showing enlarged liver and lipid accumulation (Fig. 1D, H and I). Consistent with lipid deposition, the lipogenic genes of 

next investigated the effect of T0901317 administration on PPARγ target genes. As shown in Fig. 3G, HFD mice had elevated expression levels of PPARγ target genes, including the lipogenic genes of Fabp4, Lpl (the gene responsible for hydrolysis of lipoprotein-bound triglycerides supplying fatty acids and glycerol to adipose depot) and Cd36 (the gene responsible for fatty acid transport to adipose tissue), but had reduced expression of the insulin-sensing gene of adiponectin in epididymal fat compared with ND mice. Surprisingly, all the previously mentioned PPARγ target genes were decreased by T0901317 treatment in HFD mice, suggesting an antagonising effect of LXR on the PPARγ-mediated transcriptional activity, and this finding was supported by in vitro studies. Figure 3H showed that the binding of PPARγ to PPRE in the presence or absence of pioglitazone or T0901317 in differentiated 3T3-L1 adipocytes in EMSA analysis. Values are mean ± s.e.m., *P < 0.05 and **P < 0.01.

LXR activation induces lipid accumulation in the liver

Generally, increased lipolysis and FFA secretion from adipose tissue lead to ectopic fat accumulation, which was indeed found in T0901317-treated HFD mice showing enlarged liver and lipid accumulation (Fig. 1D, H and I). Consistent with lipid deposition, the lipogenic genes of Srebp-1c and Fasn in the liver were significantly increased in T0901317-treated HFD mice. In contrast to epididymal fat, the Lpl gene, responsible for hydrolysis of lipoprotein-bound triglycerides supplying fatty acids for liver, was significantly induced by T0901317 administration in HFD mice. By contrast, Cd36, the gene for fatty acid transport, was not changed by T0901317 treatment (Fig. 4A), suggesting that a decreased fatty acid influx in adipose tissue might facilitate more fatty acid flow to the liver resulting in triglyceride synthesis. Furthermore, the genes responsible for fatty acid oxidation including Cpt1a and Ppara were decreased, supporting lipid deposition in the liver (Fig. 4B).
LXR impairs adipose expansion and function

Y DONG and others

LXR activation induces insulin resistance in epididymal fat and in the whole body

The change of morphology and metabolism of adipose tissue is usually associated with impaired glucose utilisation in adipose tissue, leading to impaired glucose homeostasis in the whole body; therefore, we studied whether LXR affected the glucose response and insulin sensitivity in T0901317-treated HFD mice.

Fifteen weeks of HFD successfully induced diabetes and insulin resistance in C57BL/6 mice; these mice showed a significantly higher glucose and insulin response in IPGTT than mice on ND (Fig. 5A, B, C and D). Although the glucose response was comparable in IPGTT between HFD and T0901317-treated HFD mice (Fig. 5A and B), the insulin response of T0901317-treated HFD mice was significantly higher than that of HFD mice, implicating a decrease in insulin sensitivity with T0901317 treatment (Fig. 5C and D). The decreased insulin function was further confirmed by ITT. As shown in Fig. 5E and F, the area under the curve of glucose was significantly higher in T0901317-treated HFD mice after insulin overloading, indicating decreased whole-body insulin action by LXR activation.

To further clarify the effect of LXR on glucose uptake in adipose tissue, we studied the glucose utilisation in vitro. In differentiated 3T3-L1 adipocytes, both 1 and 10 μM T0901317 treatments decreased basal glucose uptake, as well as diminished the glucose uptake increase stimulated by exogenous 100 nM insulin (Fig. 5G).

In accord with these results, the typical markers of insulin signalling activity, Akt phosphorylation and GLUT4 protein translocation to the membrane after insulin loading were markedly decreased in epididymal fat of T0901317-treated HFD mice (Fig. 5H and I). Consistent with increased insulin levels, histological analysis revealed enlarged and an increased number of pancreatic islets, as well as larger areas of islets in T0901317-treated HFD mice (Fig. 5J, K and L).

Discussion

The present study demonstrates that LXR activation causes a reduction in adipose tissue mass but results in massive fatty livers, accompanied by increased adipocyte apoptosis and lipolysis, as well as decreased PPARγ-mediated transcriptional activity in adipose tissue. Moreover, impaired adipose expansion by LXR activation is associated with decreased insulin signalling in adipose tissue and decreased insulin sensitivity of the whole body in HFD-fed mice.

Consistent with the findings of Beaven and coworkers and Korach-André and coworkers (Korach-Andre et al. 2011, Beaven et al. 2013) who described that global LXR deletion in the setting of obesity shifts the programme of de novo lipogenesis from the liver to adipose tissue, we found an opposite phenotype, showing that LXR activation caused reductions in fat pads but liver enlargement and fatty steatosis. Loss of adipocytes through apoptosis by LXR activation might be an important process leading to fat mass reduction in the present study. Apoptosis of adipose tissue is relatively poorly studied compared to that in other tissues; yet, increased adipocyte apoptosis has been recently proposed to contribute to obesity and to differences in regional fat distribution or expansion and insulin resistance, in both obese animals and humans (Alkhouri et al. 2010, Tinahones et al. 2013, Bennett et al. 2014). As shown in the present study and others
LXR impairs adipose expansion and function

(Alkhouri et al. 2010, Tinahones et al. 2013, Bennett et al. 2014), increased adipocyte apoptosis usually results in macrophage infiltration and inflammation, which are associated with insulin resistance. Furthermore, insulin resistance induced by inflammatory factors is reversed by interference with apoptosis initiation via CASP3/7 inhibition.

Lipid storage is determined by the balance between fat synthesis (lipogenesis) and fat breakdown (lipolysis/fatty acid oxidation). Lipogenesis encompasses the
processes of fatty acid synthesis and triglyceride synthesis and takes place in both the liver and adipose tissue, and it is the crucial process for adipose expansion. Although LXR agonists are well-characterised inducers of hepatic lipogenesis via SREBP-1c and its response genes FASN, ACC and SCD1 (Schultz et al. 2000, Yoshikawa et al. 2001), we did not find a role of LXR activation in lipogenesis in adipocytes, although significantly increased expression of Srebp-1c and Fasn were found in epididymal fat. This finding is supported by Archer and coworkers (Archer et al. 2013) who showed increased SREBP-1c expression in visceral fat but lower visceral fat mass. These results suggest that at least in rodent adipose tissue, LXR and SREBP-1c are not the primary regulator of lipogenesis; this conclusion is supported by data from SREBP-1c/−/− mice and mature adipocytes isolated from LXRα/β−/− mice, both of which showed a similar level of lipogenesis to that in their wild-type littersmates (Kalaany et al. 2005).

However, increased basal lipolysis supported by increased fasting FFA levels in the circulation by T0901317 treatment might contribute to reduced adipocyte size and fat mass by LXR activation. Similar treatment with GW3965 resulted in smaller fat cells (Archer et al. 2013), indicative of increased triglyceride utilisation. An effect of LXR on basal lipolysis is also supported by findings in human adipocytes and adipose tissue LXRα-knockout (AaKo) mice (Stenson et al. 2011, Dib et al. 2014). Downregulation of lipid droplet-coating proteins of PLIN1, as found in our present study might be the molecular mechanism, for low levels or absence of PLIN1, has been implicated in enhanced spontaneous lipolysis both in mice and humans (Martinez-Botas et al. 2000, Tansey et al. 2001, Mottagui-Tabar et al. 2003).

In addition, we found that the insulin-induced anti-lipolytic action was significantly blunted by LXR activation. Insulin is known to suppress lipolysis by inactivating HSL (Choi et al. 2010). In T0901317-treated HFD mice, we did find HSL phosphorylation and its upstream molecular of ATGL were higher than those in vehicle-treated HFD mice with same dose of insulin administration, supporting the reduction of fat mass was associated with lipolysis. Furthermore, the expression levels of Cd36 and Lpl (proteins involved in lipid clearance from the circulation and deposition in adipose tissue as triglycerides) were decreased, which might contribute to increased TG and FFA levels in the circulation and decreased fat mass in T0901317-treated HFD mice. PPARγ is critically required for adipose tissue expansion by increasing lipogenesis and adipocyte proliferation. Indeed, consistent with reductions in fat mass and increases in adipocyte apoptosis, we found that PPARγ-mediated transcriptional activity was inhibited by LXR, which was supported by the reduced PPARγ–PPRE binding activity in T0901317-treated 3T3-L1 cell, as well as the inhibited PPARγ target genes expression in epididymal fat in T0901317-treated HFD mice. Although the mechanism of LXR interfering with the PPARγ pathway was not further studied, the fact that LXR shares its heterodimerising partner (that is RXR) with PPARs and sometimes competes for the same DNA response elements suggests that LXR could affect PPAR signalling (Ide et al. 2003, Yoshikawa et al. 2003).

Impaired adipose expansion was generally associated with ectopic lipid accumulation and insulin resistance. Indeed in the present study, moderate hepatomegaly and steatosis, as well as higher insulin levels, decreased insulin sensitivity and enlarged pancreatic islets were consistent with other animal models of impaired adipose expansion and human lipoatrophy or lipodystrophy (Garg 2011, Wang et al. 2013). The role of LXR activation in fatty acid synthesis in the liver is well established (Cha & Repa 2007, Baranowski 2008). Indeed, our study also found that typical genes of lipogenesis, including Srebp-1c and Fasn, were significantly induced by T0901317 administration. Importantly, we further found increased Lpl and decreased Ctp1a and Ppara in the liver, suggesting an increased capacity of fatty acid intake and decreased fatty acid oxidation in the liver, which might also be another mechanism for hepatic steatosis by LXR activation. It is worth pointing out that pancreatic islets in T0901317-treated mice generated double the insulin levels, which at least suggests insulin resistance instead of a direct stimulating effect of LXR activation, for blood glucose responses in T0901317-treated mice were comparable instead of lower than those in HFD mice, and this finding was supported by ITT results which showed that T0901317-treated mice had a blunted glucose response to exogenous insulin. Decreased insulin efficiency was most likely associated with increased FFA levels and decreased levels of the insulin-sensitising adipokines of adiponectin and leptin.

Glucose uptake in adipose tissue influences whole-body glucose homeostasis. The effect of T0901317 on glucose utilisation in adipocyte is not consistent (Laffitte et al. 2003, Stenson et al. 2009, Pettersson et al. 2013). In our study, we found that T0901317 decreased both basal and insulin-stimulated glucose uptake in 3T3-L1 cells. Decreased glucose uptake in adipose tissue was supported by insulin-induced Akt activity and GLUT4 membrane

http://jme.endocrinology-journals.org DOI: 10.1530/JME-16-0196 © 2017 Society for Endocrinology Published in Great Britain

Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 08/25/2019 05:47:09PM via free access
translocation in T0901317-treated mice. This result is consistent with the in vitro findings of other studies either using the same cell model or primary human adipocytes (Stenson et al. 2009, Pettersson et al. 2013). Although other studies have shown unchanged or increased basal glucose uptake, the discrepancies between these studies could result from differences in agonists, in vitro cell models and treatment conditions. Despite decreased glucose uptake in adipocytes, whole-body glucose homeostasis was not changed in T0901317-treated mice. This finding probably resulted from the compensatory increase in insulin secretion and pancreatic islet enlargement. The relatively stable glucose metabolism might also be due to decreased gluconeogenesis by LXR activation (Laffitte et al. 2003, Liu et al. 2006, Commerford et al. 2007). A few studies addressing the role of LXR in carbohydrate metabolism have shown improved glucose tolerance by LXR activation in vivo; however, no study has investigated the fat mass change. No change of systemic glucose homeostasis was shown in ob/ob female mice with T0901317 treatment in the study by Archer and coworkers, in which they also found decreased visceral fat mass with GW3965 treatment (Archer et al. 2013). Thus, the adipose tissue loss in these studies might be the reason for the discrepancies. Decreased adipose mass is possibly only caused by a relatively higher dose or longer treatment period, as in our study and the study by Archer and coworkers.

The ability of LXR agonists to promote reverse cholesterol transport and inhibit inflammatory response in macrophages makes them extremely attractive therapeutic targets in human metabolic diseases (Zelcer & Tontonoz 2006). However, administration of LXR agonists to mice induces lipogenesis in the liver and raises plasma triglyceride levels (Chisholm et al. 2003). In particular, we suggest that LXR activation can impair adaptive adipose expansion, lead to ectopic lipid deposition in the liver and worsen insulin resistance under the metabolic condition of relative energy surplus. Our data suggest that the comprehensive effect of LXR activation on metabolism may attribute to its influences on many organs, particularly the adipose tissue and the liver. The anti-diabetic and anti-atherosclerotic effects of LXR activation will likely be limited unless their effects on adipose expansion and lipogenetic process in liver can be pharmacologically separated from the effects on glucose metabolism and inflammatory response.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/JME-16-0196.


Received in final form 26 January 2017
Accepted 30 January 2017